It also specifically observes the changes in choroidal thickness and CVI after multiple anti VEGF treatments in acute phase BRVO patients, as well as the changes in choroidal thickness and CVI during stable phase BRVO after macular edema subsides and treatment is stopped for at least six months. The gene discussed is VEGFA; the disease is macular retinal edema.